Bristol Myers Squibb’s Zeposia angles for lucrative ulcerative colitis nod with new data

Bristol Myers Squibb’s Zeposia angles for lucrative ulcerative colitis nod with new data

Bristol Myers Squibb notched a big win with its recent approval of multiple sclerosis drug Zeposia, a Celgene pipeline pickup with blockbuster aspirations. Not content to ride its way to success in M…
Read More

Leave a Reply

Your email address will not be published. Required fields are marked *